URSA - Drugs and Clinicals Solv-2: leaderboard
URSA (Insilico Medicine, 2026) evaluates synthesis planning: each proposed route must end in purchasable building blocks, be structurally valid and pass the ChemCensor precedent-based plausibility check for every reaction (Solv-2). This board is the percent of 100 approved drugs and clinical candidates solved at Solv-2 in the open URSA-minor-1.1.0-U2 configuration; higher is better.
Metric: Solv-2 solved targets (%; share of the 100 URSA-drugs&clinicals-2026 approved drugs and clinical candidates with stock-terminated routes proposed for those targets whose every reaction also passes the ChemCensor precedent-based plausibility check (Solv-2), best of up to 10 routes per target, URSA-minor-1.1.0-U2 configuration with ChemCensor v1.2.0 and the U2 USPTO precedent database, shared stock of 255,365 building blocks; default reasoning effort; higher is better). Source: arxiv.org. Saturation forecast: Around February 2027. 17 models tracked.
Top models
| # | Model | Score | Overall rank |
|---|---|---|---|
| 1 | Gemini 3.1 Pro (Preview) | 38 | #94 |
| 2 | GPT-5.5 | 35 | #49 |
| 3 | Claude Opus 4.8 | 27 | #56 |
| 4 | Grok 4.1 | 24 | #476 |
| 5 | Claude Opus 4.7 | 22 | #79 |
| 6 | Claude Opus 4.5 | 19 | #156 |
| 7 | Qwen 3.5 397B A17B | 15 | #246 |
| 8 | Claude Opus 4.6 | 14 | #102 |
| 9 | Kimi K2.5 | 10 | #256 |
| 10 | GLM-5 | 10 | #260 |
| 11 | Claude Sonnet 4.6 | 8 | #161 |
| 12 | Claude Sonnet 4.5 | 7 | #250 |
| 13 | GPT-5.2 | 7 | #176 |
| 14 | GPT-5.4 | 6 | #123 |
| 15 | DeepSeek V3.2 | 1 | #406 |
No result here: #1 Claude Fable 5.2, #2 Gemini 4 Carbon, #5 Claude Opus 5.5.
Interactive version: theaggregate.ai/benchmark?slug=ursa-drugs-and-clinicals-solv-2 · How It Works · Data refreshed daily, snapshot 2026-11-13.